Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 16/20 | 0.75 |
| ▸ | ROCK1 | Q13464 | 6/20 | 0.75 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.75 |
| ▸ | CDC42BPA | Q5VT25 | 3/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.57 |
| ▸ | MTOR | P42345 | 2/20 | 0.56 |
| ▸ | MYLK4 | Q86YV6 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3249897 | 0.88 | ROCK2 (0.78) | ROCK2ROCK1CYP2C9CDC42BPACYP3A4 | |
| SCHEMBL3247307 | 0.87 | ROCK2 (0.76) | ROCK2ROCK1CYP2C9CDC42BPACYP3A4 | |
| SCHEMBL3241830 | 0.86 | ROCK2 (0.78) | ROCK2ROCK1CYP2C9CDC42BPACYP3A4 | |
| SCHEMBL3253046 | 0.86 | ROCK2 (1.00) | ROCK2ROCK1CYP2C9CDC42BPACYP3A4 | |
| SCHEMBL3247657 | 0.85 | ROCK2 (0.80) | ROCK2ROCK1CYP2C9CDC42BPACYP3A4 | |
| SCHEMBL3124743 | 0.85 | ROCK2 (0.76) | ROCK2ROCK1CYP2C9CDC42BPACYP3A4 | |
| SCHEMBL3238663 | 0.85 | ROCK2 (0.77) | ROCK2ROCK1CYP2C9CDC42BPACYP3A4 | |
| SCHEMBL19661755 | 0.85 | ROCK2 (0.69) | ROCK2ROCK1CYP2C9CDC42BPACYP3A4 | |
| SCHEMBL3123814 | 0.84 | ROCK2 (0.82) | ROCK2ROCK1CYP2C9CDC42BPACYP3A4 | |
| SCHEMBL13391269 | 0.83 | ROCK2 (0.71) | ROCK2ROCK1CYP2C9CDC42BPACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010036316-A1 | UREA AND CARBAMATE COMPOUNDS AND ANALOGS AS KINASE INHIBITORS | FENG YANGBO (US) | 2010-04-01 | — | — | WO | claimed |
| US-20140179697-A1 | DISUBSTITUTED OCTAHYDROPYRROLO[3,4-c]PYRROLES AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-06-26 | — | — | US | disclosed |
| WO-2010036316-A1 | UREA AND CARBAMATE COMPOUNDS AND ANALOGS AS KINASE INHIBITORS | FENG YANGBO (US) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179697-A1 | DISUBSTITUTED OCTAHYDROPYRROLO[3,4-c]PYRROLES AS OREXIN RECEPTOR MODULATORS | HCRTR2, HCRTR1, OXTR | ROCK2 2416/4885ROCK1 2077/4885CYP2C9 2554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.